Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3 Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule, implementation, and legislation Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the elife sciences ecosystem Oppose drug importation proposals Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2026 · second_quarter · Q2
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support robust funding for the NIH in FY2027 appropriations
Source: Senate LDA
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support full funding across HHS departments
Support robust domestic supply chain development and manufacturing ecosystem
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2026 · first_quarter · Q1
Support robust domestic supply chain development and manufacturing ecosystem
Support full funding across HHS departments
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2025 · fourth_quarter · Q4
Support full funding across HHS departments
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support robust domestic supply chain development and manufacturing ecosystem
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2025 · third_quarter · Q3
Support full funding across HHS departments
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Support legislation to modernize the U.S. Preventive Services Task Force (USPSTF) Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support legislation providing Medicare coverage for anti-obesity medication Submit comments with regards to CMS' MDPNP guidance for IPAY28
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Oppose Most Favored Nations Executive Order
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support robust domestic supply chain development and manufacturing ecosystem
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2025 · second_quarter · Q2
Support legislation to reform Congressional Budget Office scoring of health care legislation Support full funding across HHS departments
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Support legislation to modernize the U.S. Preventive Services Task Force (USPSTF) Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support robust domestic supply chain development and manufacturing ecosystem
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Oppose Most Favored Nations Executive Order
Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the MDPNP Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support legislation providing Medicare coverage for anti-obesity medication Submit comments with regards to CMS' MDPNP guidance for IPAY28
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
Support legislation to provide immediate coverage for breakthrough device Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2025 · first_quarter · Q1
Support legislation to reform Congressional Budget Office scoring of health care legislation Support full funding across HHS departments
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Support legislation to modernize the U.S. Preventive Services Task Force (USPSTF) Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user (Medical Device Electronic Labeling Act)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2024 · fourth_quarter · Q4
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the MDPNP Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support improvements to manufacturer and stakeholder input processes within the Medicare Drug Price Negotiation Program Support legislation providing Medicare coverage for anti-obesity medication Support improvements to manufacturer engagement process for Small Biotech Exemption within MDPNP
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2024 · third_quarter · Q3
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Support legislation to modernize the U.S. Preventive Services Task Force (USPSTF) Support electronic labeling for all medical devices, regardless of setting of use or the intended user (Medical Device Electronic Labeling Act)
Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support improvements to manufacturer and stakeholder input processes within the Medicare Drug Price Negotiation Program Support legislation providing Medicare coverage for anti-obesity medication Support improvements to manufacturer engagement process for Small Biotech Exemption within MDPNP CMS CY2025 Hospital Outpatient Prospective Payment System (OPPS) proposed rule
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2024 · second_quarter · Q2
Support robust domestic supply chain development and manufacturing ecosystem
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
Support promulgation of TCET final rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2024 · first_quarter · Q1
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D
Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2023 · fourth_quarter · Q4
Support legislation to reform Congressional Budget Office scoring of health care legislation
Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
Support R&D and NOL tax incentives, Orphan Drug Tax Credits, repeal R&D tax amortization
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2023 · third_quarter · Q3
Support NIH research funding Support promulgation of TCET rule Support breakthrough device coverage bill Support bipartisan PAHPA reauthorization
Oppose proposals to reduce data exclusivity Oppose proposals to restrict data uses Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
Address concerns with provisions of patent litigation reform, including inter partes review Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic R&D
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2023 · second_quarter · Q2
Labor/HHS/Ed Appropriations: Drug Pricing, FDA, NIH, biodefense/pandemic, CDC, science/math education, and strategic stockpile funding and preparation; Coronovirus funding and response FDA Appropriations; PTO Appropriations; eLabeling appropriations language. Drug Pricing proposals, Orphan Drug Tax Credit; semiconductor/CHIPS funding; oppose budget reconciliation with drug pricing
Support NIH research funding Support implementation of 21st Century Cures Act Support promulgation of TCET rule Support alternatives to animal research Support breakthrough device coverage bill Support bipartisan PAHPA reauthorization
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the MDPNP Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support legislation providing Medicare coverage for anti-obesity medication
Support breakthrough device coverage bill Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support robust domestic supply chain development and manufacturing ecosystem
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Oppose policy proposal requiring Access Plans to be part of licensing agreements for NIH owned inventions Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Support legislation to modernize the U.S. Preventive Services Task Force (USPSTF) Support electronic labeling for all medical devices, regardless of setting of use or the intended user (Medical Device Electronic Labeling Act)
Support promulgation of TCET final rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening Support timely reauthorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Support robust domestic supply chain development and manufacturing ecosystem
Support legislation to reform Congressional Budget Office scoring of health care legislation
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Support legislation to reform Congressional Budget Office scoring of health care legislation
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Oppose policy proposal requiring Access Plans to be part of licensing agreements for NIH owned inventions Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D
Support promulgation of TCET final rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening Support timely reauthorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
Support robust domestic supply chain development and manufacturing ecosystem
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape
Support legislation to reform Congressional Budget Office scoring of health care legislation
Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D
Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support improvements to manufacturer and stakeholder input processes within the Medicare Drug Price Negotiation Program Support legislation providing Medicare coverage for anti-obesity medication
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), SENATE
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape
Support legislation to reform Congressional Budget Office scoring of health care legislation
Support promulgation of TCET final rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening
Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
Support robust domestic supply chain development and manufacturing ecosystem
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), SENATE
Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic R&D
Support promulgation of TCET rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening
Oppose drug importation proposals Support diversity in clinical trial policy Support medical device change control plans legislation Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs. Support legislation providing for e-labeling of medical devices
Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support value-based purchasing provision, but opposed line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Labor/HHS/Ed Appropriations: Drug Pricing; FDA; NIH; biodefense/pandemic; CDC; science/math education; U.S. Preventive Services Task Force; eLabeling; Orphan Drug Tax Credit Support legislation to reform Congressional Budget Office scoring of health care legislation
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Oppose drug importation proposals Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
Support FDA user fee programs and review process consistency and predictability. Support FDA modernization practices Support legislation proposing coverage for multicancer screening Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices Support public education campaign on pandemic preparedness Oppose drug importation proposals Support diversity in clinical trial policy Support medical device change control plans legislation Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan Pandemics and All Hazards Preparedness Reauthorization Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation providing for e-labeling of medical devices
Support R&D and NOL tax incentives, Orphan Drug Tax Credits, repeal R&D tax amortization
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3 Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule, implementation, and legislation Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the elife sciences ecosystem Oppose drug importation proposals Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
Address concerns with provisions of patent litigation reform, including inter-partes review Support STRONGER Patents Act Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic R&D Support incentives for onshore and near shore critical manufacturing capacities
Banking reform, Federal Reserve and Treasury oversight of regional banks
Oppose domestic manufacturing/procurement mandates in NDAA for pharmaceutical products, APIs, & medical devices
Support FDA user fee programs and review process consistency and predictability. Support FDA modernization practices Support legislation proposing coverage for multi-cancer screening Support FDA modernization efforts and vaccine awareness Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices Support improvements to the Strategic National Stockpile for pandemic testing preparedness Support public education campaign on pandemic preparedness Support re-authorization of Rare Pediatric Disease Priority Review Voucher (RPD PRV) program Oppose drug importation proposals Support diversity in clinical trial policy Support medical device change control plans legislation Oppose drug pricing proposals that allow Medicare to directly negotiate prices Support bipartisan Pandemics and All Hazards Preparedness Re-authorization Support alternatives to animal testing in trials Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act)
Support R&D and NOL tax incentives, Orphan Drug Tax Credits, repeal of R&D tax amortization
Oppose proposals to reduce data exclusivity Oppose proposals to restrict data uses Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics Support USTR resolution process with Mexico trade authority to allow biotech corn into Mexican market
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE